Deutsche Bank has published a research report on Medtronic (NYSE:

), maintaining their current position. In the report, Deutsche Bank wrote, "We are not disillusioned, nor do we think the new CEO is, about the enormity of the task ahead. MDT has struggled for a decade; given its sheer size it will take time to turn around. However, unlike some undergoing turnarounds (e.g. Boston Scientific), we believe Medtronic has a better existing foundation." Deutsche Bank rated Medtronic a BUY with a price target of $43.00. Medtronic closed Tuesday at $33.10.